Evonik Bolsters its Capabilities for Customized RESOMER Powder Biomaterials

Evonik has expanded its capacities for RESOMER powder biomaterials at its Darmstadt, Germany site, enabling the specialty chemicals company to offer an advanced solvent-free micronization technology for producing custom powders with different particle sizes and material properties. With the new production capacities, Evonik also intends to expand its own portfolio of standard RESOMER powders for medical devices to open up customized material solutions for precision implants or aesthetic applications.
 
Evonik’s new technology platform will open up opportunities to collaborate with customers to co-design and manufacture specialized RESOMER powders with customized particle sizes for a various medical applications. This systems-oriented approach to developing solutions with partners along the value chain is an important part of the 10-year vision adopted by Evonik’s life sciences division, which inspires a customer-centric, systems-thinking mindset.
 
“Our micronization technology will empower customers to work with powders in the grade that they need—enabling them to further explore other aesthetic and medical treatments with our innovative biomaterials,” said Andreas Karau, global head of Medical Device Solutions at Evonik’s Health Care business line.
 
Evonik’s solvent-free micronization technology can be offered from small laboratory scale to commercial manufacturing. This allows customers to test and optimize their own formulations with smaller volumes of technical material before ordering larger commercial quantities that are manufactured under ISO 13485 and GMP standards.
 
Evonik provides materials for the medical device and pharmaceutical markets. Commercially available for more than 30 years, RESOMER is Evonik’s brand of bioresorbable polymers, renowned for its use in the production of resorbable medical devices and pharmaceuticals, with an established reputation for efficacy, biocompatibility, and safety. The RESOMER powders provided by Evonik are of a quality suitable for implantable medical devices, adhering to stringent ISO 13485 and GMP compliance standards. The new micronization platform builds on Evonik’s extensive polymer design and processing expertise and experience in a wide range of applications.
 
Evonik is active in more than 100 countries worldwide. It generated €15.3 billion in sales and €1.66 billion in operating profit (adjusted EBITDA) last year. Evonik goes far beyond chemistry to create sustainable solutions for customers.